Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant 177Lu-DOTATATE for Resectable Pancreatic Neuroendocrine Tumors
NCT04385992Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Mar 2020
- Primary completion
- Jan 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Pancreatic neuroendocrine tumor (PanNET), sponsored by IRCCS Ospedale San Raffaele. Started Mar 2020; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT04385992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385992.